Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma

Patent metadata

Field	Value
Publication number	US-11058691-B2
Application number	US-201716343323-A
Country	US
Kind code	B2
Filing date	Nov 7, 2017
Priority date	Nov 8, 2016
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I).

First claim

The invention claimed is:

1. A method of lowering intraocular pressure in a patient with normal tension glaucoma, comprising administering to the patient a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof
R—X—Y—ONO 2
(I)
wherein R is the prostaglandin residue of formula (II):

wherein
X is —O—;
Y is a bivalent radical having the following meaning:
straight or branched C 1 -C 10 alkylene.

2. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

3. The method of claim 1 , wherein the compound of formula (I) is compound (1).

4. The method of claim 1 , wherein the compound of formula (I) is administered as ophthalmic pharmaceutical formulation comprising ophthalmically acceptable excipients.

5. The method of claim 1 , wherein the compound of formula (I) is administered with a further active principle selected from the group consisting of a beta-blocker, a carbonic anhydrase inhibitor and an adrenergic agonist.

6. The method of claim 3 , wherein compound (1) is administered with a further active principle selected from the group consisting of a beta-blocker, a carbonic anhydrase inhibitor and an adrenergic agonist.

7. The method of claim 5 , wherein the compound of formula (I) and the further active principle are administered as ophthalmic pharmaceutical formulation comprising ophthalmically acceptable excipients.

Assignees

• Bausch & Lomb
• Nicox Sa

Inventors

• Vittitow Jason Lamar
• Cavet Megan Elizabeth

Classifications

• C07C405/0041 Primary

  containing nitrogen · CPC title

• A61K31/5575 Primary

  having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title